Clinical trials: Obesity (BMI>30)
Hypertension
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
- Trial name
- ATTAIN (NCT00772577)
- Testing
- Aliskiren Hydrochlorothiazide, Ramipril
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and…
- Trial name
- MEASURE (NCT07639684)
- Testing
- ESG with OverStitch
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Overweight and Obese Adults, Obese Patients (BMI ≥ 30 kg/m²)
Eatit's Obesity Intervention: Effects on Weight, Eating Habits and Health
Obesity is a growing public health problem in Sweden, but access to care varies depending on geographical location. Eatit´s multimodal digitally dietitian-supported lifestyle intervention offers an accessible treatment…
- Trial name
- NCT07183228
- Testing
- Lifestyle Intervention for Obesity
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Eatit AB
Healthy
Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women
This study will assess if itraconazole will affect the blood levels of Duavee when they are given together. This study will also assess if a subject's body size affects the blood levels of Duavee.
- Trial name
- CE/BZA (NCT02100553)
- Testing
- CE/BZA, Itraconazole
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals
The purpose of this study is to determine whether low level laser light therapy is effective in reducing circumference of the waist, hips and upper abdomen in obese individuals.
- Trial name
- NCT01821352
- Testing
- Erchonia Obesity Laser
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Erchonia Corporation
Hypertension
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
To evaluate the blood pressure lowering effects of the combination of aliskiren 300 mg and HCTZ 25 mg in obese patients with essential hypertension inadequately treated with HCTZ 25 mg, compared to irbesartan or amlodipine with…
- Trial name
- NCT00219115
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 493 people
- Sponsor
- Novartis
Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities
The goal of this randomized, double-blind, placebo-controlled, phase IIa study is to demonstrate superiority on body weight reduction of two different doses of twice daily distal jejunal-release dextrose beads formulations (APHD…
- Trial name
- NCT07008456
- Testing
- APHD-012, APHD-002, APHP-012
- Where
- 6 sites in Georgia
- Volunteers
- 102 people
- Sponsor
- Aphaia Pharma US LLC
Obesity &Amp;Amp;Amp; Overweight, Obesity (Body Mass Index &Amp;Amp;Amp;Amp;gt;30 kg/m2)
A Consumer Health Study Evaluating the Impact of Pivit on Weight Loss and Appetite in Overweight Individuals
The purpose of this study is to observe the impact of Pivit on body weight in overweight individuals. Additionally, the study aims to observe the impact of the product on appetite, hunger, cravings, and general well-being via…
- Trial name
- NCT07245914
- Testing
- The Study Product (Pivit)
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Olfactive Biosolutions, Inc.
Obesity (BMI>30), Obesity & Overweight
Allurion Gastric Balloon PAS
The primary purpose of this study is to confirm the safety profile results for the Allurion Gastric Balloon System (AGBS).
- Trial name
- NCT07684664
- Testing
- Active Elipse Device
- Volunteers
- 250 people
- Sponsor
- Allurion Technologies
Obesity / Overweight, Obesity (BMI Equal to or >30)
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
This study is designed as a single-blind, placebo-controlled, randomized, parallel-group trial. Subjects will be randomized in a 2:1 ratio to receive either NKS-3 or matching placebo, with a total planned enrollment of 31…
- Trial name
- SERENITY-1 (NCT07882654)
- Testing
- Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120
- Where
- Tunisia
- Volunteers
- 31 people
- Sponsor
- EktaH
Central Abdominal Bulging
Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects
This is a multi-center, randomized, placebo-controlled, double-blind study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging in obese subjects.
- Trial name
- NCT02568319
- Testing
- LIPO-202
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Neothetics, Inc
Obesity, Overweight, or Chronic Weight Management
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at…
- Trial name
- ACCESS (NCT06693843)
- Testing
- Aleniglipron
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity
Effectiveness and Safety Study of LAP-BAND Treatment in Subjects With BMI >/= 30 kg/m2 and < 40 kg/m2
The purpose of this study is to determine whether the LAP-BAND system is safe and effective in subjects with BMI ≥ 30 kg/m2 and < 40 kg/m2.
- Trial name
- NCT00570505
- Testing
- LAP-BAND System
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- Apollo Endosurgery, Inc.
Obese Adults
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
- Trial name
- NCT07838740
- Testing
- VK2735 Drug
- Where
- 2 sites in United States
- Volunteers
- 270 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity, Overweight
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- ACCESS II (NCT06703021)
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Overweight, or Chronic Weight Management
Aleniglipron Phase 2 Body Composition Study
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity.
- Trial name
- NCT07169942
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics